McKesson Corporation Q2 2027 Earnings Recap

McKesson shares were roughly flat, up 0.3% after earnings. The quarter included higher revenue and EPS and a raised full-year EPS outlook, but the market reaction was muted.

Key Takeaways

• Second-quarter revenue increased 8% year over year, with growth across all segments; adjusted EPS rose 18%.
• McKesson raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, from $44.20–$45 previously.
• The company completed its acquisition of Precision Medicine Group, adding clinical research and biopharma market-access capabilities.
• McKesson also agreed to make a strategic investment in Option Care Health; the transaction remains subject to customary closing conditions, including stockholder and regulatory approvals.
• Management cited drug innovation and stable utilization as supportive trends in oncology and multispecialty, and highlighted the continued expansion of its retina and ophthalmology platform.